CO6430434A2 - Nuevas composiciones de vacunas con pertussis acelular y método de fabricación de las mismas - Google Patents
Nuevas composiciones de vacunas con pertussis acelular y método de fabricación de las mismasInfo
- Publication number
- CO6430434A2 CO6430434A2 CO11063979A CO11063979A CO6430434A2 CO 6430434 A2 CO6430434 A2 CO 6430434A2 CO 11063979 A CO11063979 A CO 11063979A CO 11063979 A CO11063979 A CO 11063979A CO 6430434 A2 CO6430434 A2 CO 6430434A2
- Authority
- CO
- Colombia
- Prior art keywords
- vaccine
- manufacturing
- pertussis
- antigens
- accelular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona con una vacuna combinada que comprende una mezcla de antígenos para protección contra enfermedades tales como difteria, tétanos, tos ferina acelular e infecciones causadas por Haemophilus influenzae y virus de la polio. La presente invención también ser relaciona con la inclusión de antígenos para protección contra infecciones causadas por virus de la hepatitis y otros patógenos, tal que la administración de la vacuna puede inmunizar simultáneamente al sujeto contra más de un patógeno. La invención en particular se relaciona con una vacuna combinada completamente líquida y estable que comprende los antígenos indicados más arriba y con los métodos para fabricar dicha vacuna.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2438DE2008 | 2008-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6430434A2 true CO6430434A2 (es) | 2012-04-30 |
Family
ID=42119003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11063979A CO6430434A2 (es) | 2008-10-24 | 2011-05-24 | Nuevas composiciones de vacunas con pertussis acelular y método de fabricación de las mismas |
Country Status (14)
Country | Link |
---|---|
US (1) | US8551451B2 (es) |
EP (2) | EP2529749A1 (es) |
JP (1) | JP2012506421A (es) |
CN (1) | CN102196818A (es) |
AP (1) | AP2011005701A0 (es) |
AR (1) | AR073959A1 (es) |
BR (1) | BRPI0920630A2 (es) |
CA (1) | CA2741396A1 (es) |
CL (1) | CL2011000914A1 (es) |
CO (1) | CO6430434A2 (es) |
MA (1) | MA32819B1 (es) |
PE (1) | PE20100366A1 (es) |
RU (2) | RU2526214C2 (es) |
WO (1) | WO2010046935A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2066344T3 (pl) | 2006-09-07 | 2011-10-31 | Glaxosmithkline Biologicals Sa | Skojarzona szczepionka zawierająca inaktywowany wirus polio |
GB0822633D0 (en) * | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
EP3459562B1 (en) | 2011-01-05 | 2024-03-20 | Bharat Biotech International Limited | A combination heptavalent vaccine |
FR2985663B1 (fr) * | 2012-01-17 | 2015-03-27 | Sanofi Pasteur | Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium |
FR2992656B1 (fr) * | 2012-07-02 | 2016-10-07 | Sanofi Pasteur | Procede de production d'antigenes haemophilus influenzae type b |
PT2884996T (pt) * | 2012-08-17 | 2020-02-21 | Intervet Int Bv | Uma composição imunogénica de bactérias de leptospira mortas |
SG11201506858SA (en) * | 2013-03-08 | 2015-09-29 | Crucell Holland Bv | Acellular pertussis vaccine |
US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
SG11201600709TA (en) * | 2013-08-05 | 2016-02-26 | Glaxosmithkline Biolog Sa | Combination immunogenic compositions |
CN105861535B (zh) * | 2015-01-20 | 2019-10-25 | 中国人民解放军军事医学科学院生物工程研究所 | 伤寒糖蛋白的生物制备方法及其应用 |
CN106075428A (zh) * | 2015-07-01 | 2016-11-09 | 北京科兴中维生物技术有限公司 | 一种免疫原性组合物及其制备方法 |
CA3070039A1 (en) * | 2017-07-18 | 2019-01-24 | Serum Institute Of India Pvt Ltd. | An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof |
CN109550046B (zh) * | 2018-12-21 | 2020-08-25 | 北京民海生物科技有限公司 | 一种吸附无细胞百白破-脊髓灰质炎-b型流感嗜血杆菌联合疫苗及其制备方法 |
WO2020165920A1 (en) * | 2019-02-12 | 2020-08-20 | Biological E Limited | Multivalent vaccine composition |
CN111053898B (zh) * | 2019-12-26 | 2023-05-16 | 北京科兴中维生物技术有限公司 | 一种疫苗组合物及其应用 |
CN110917344B (zh) * | 2019-12-26 | 2022-11-04 | 北京科兴中维生物技术有限公司 | 一种液体疫苗组合物及其应用 |
WO2021176409A1 (en) | 2020-03-05 | 2021-09-10 | Sanofi Healthcare India Private Limited | Preservative combination for vaccine composition |
AU2022280871A1 (en) * | 2021-05-26 | 2023-12-07 | Emory University | Jak inhibitors for managing conditions in patients with down's syndrome or other trisomy |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE168271T1 (de) | 1992-05-23 | 1998-08-15 | Smithkline Beecham Biolog | Kombinierte impfstoffe, die hepatitis b oberfläche antigen und andere antigenen enthalten |
US5877298A (en) * | 1995-05-04 | 1999-03-02 | Connaught Lab | Acellular pertussis vaccines and methods of preparing thereof |
FR2734484B1 (fr) | 1995-05-24 | 1997-06-27 | Pasteur Merieux Serums Vacc | Composition vaccinale liquide et procede de fabrication |
US20020054884A1 (en) | 1995-06-23 | 2002-05-09 | Smithkline Beecham Biologicals, Sa | Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
SK283565B6 (sk) * | 1996-07-02 | 2003-09-11 | Connaught Laboratories Limited | Multivalentná imunogénna kompozícia a jej použitie |
ES2257769T3 (es) | 1997-09-15 | 2006-08-01 | Sanofi Pasteur Msd | Metodo para la preparacion de vacunas multivalentes. |
GB9806456D0 (en) | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
GB0313916D0 (en) | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
GB0405787D0 (en) * | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
EP1931380A2 (en) * | 2005-09-01 | 2008-06-18 | Novartis Vaccines and Diagnostics GmbH & Co. KG | Multiple vaccination including serogroup c meningococcus |
US20070065462A1 (en) * | 2005-09-21 | 2007-03-22 | Ryall Robert P | Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine |
GB0522765D0 (en) | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
-
2009
- 2009-10-22 PE PE2009001196A patent/PE20100366A1/es not_active Application Discontinuation
- 2009-10-23 US US13/125,708 patent/US8551451B2/en active Active
- 2009-10-23 EP EP11172591.7A patent/EP2529749A1/en not_active Withdrawn
- 2009-10-23 AP AP2011005701A patent/AP2011005701A0/xx unknown
- 2009-10-23 RU RU2011120308/10A patent/RU2526214C2/ru active
- 2009-10-23 WO PCT/IN2009/000600 patent/WO2010046935A1/en active Application Filing
- 2009-10-23 AR ARP090104080A patent/AR073959A1/es not_active Application Discontinuation
- 2009-10-23 JP JP2011532774A patent/JP2012506421A/ja active Pending
- 2009-10-23 BR BRPI0920630A patent/BRPI0920630A2/pt not_active Application Discontinuation
- 2009-10-23 EP EP09821706A patent/EP2362781A4/en not_active Withdrawn
- 2009-10-23 CN CN200980142461XA patent/CN102196818A/zh active Pending
- 2009-10-23 CA CA2741396A patent/CA2741396A1/en not_active Abandoned
-
2011
- 2011-04-21 CL CL2011000914A patent/CL2011000914A1/es unknown
- 2011-05-20 MA MA33875A patent/MA32819B1/fr unknown
- 2011-05-24 CO CO11063979A patent/CO6430434A2/es not_active Application Discontinuation
-
2013
- 2013-01-14 RU RU2013101418A patent/RU2634393C2/ru active
Also Published As
Publication number | Publication date |
---|---|
CL2011000914A1 (es) | 2012-01-20 |
JP2012506421A (ja) | 2012-03-15 |
US8551451B2 (en) | 2013-10-08 |
PE20100366A1 (es) | 2010-05-21 |
AR073959A1 (es) | 2010-12-15 |
AP2011005701A0 (en) | 2011-06-30 |
EP2529749A1 (en) | 2012-12-05 |
BRPI0920630A2 (pt) | 2016-01-12 |
RU2013101418A (ru) | 2014-07-20 |
MA32819B1 (fr) | 2011-11-01 |
CA2741396A1 (en) | 2010-04-29 |
RU2526214C2 (ru) | 2014-08-20 |
EP2362781A1 (en) | 2011-09-07 |
CN102196818A (zh) | 2011-09-21 |
RU2011120308A (ru) | 2012-11-27 |
EP2362781A4 (en) | 2012-12-05 |
WO2010046935A1 (en) | 2010-04-29 |
RU2634393C2 (ru) | 2017-10-26 |
US20110206726A1 (en) | 2011-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6430434A2 (es) | Nuevas composiciones de vacunas con pertussis acelular y método de fabricación de las mismas | |
CO6430435A2 (es) | Nuevas vacunas combinadas con células completas de pertussis y método de fabricación de las mismas | |
BR112013017171A2 (pt) | vacina de combinação imunogênica estável, processo de preparação de vacina de combinação estável, método de uso de moléculas antigênicas e método de administração a indivíduos humanos | |
PH12019500289A1 (en) | Vaccines directed against a human enteroviruses | |
MX2023000211A (es) | Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas. | |
PH12014501133A1 (en) | Compositions and methods for treating hepatitis c virus | |
MX346625B (es) | Mutantes de virus de influenza y usos para los mismos. | |
UY30169A1 (es) | Nuevos productos farmacéuticos | |
BR112012004698A2 (pt) | métodos de redução de atividade virucida em composições de pcv-2 e composições de pcv-2 com uma imonugenicidade aprimorada. | |
BR112012033767A2 (pt) | processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina. | |
WO2008039171A3 (en) | Inactivating pathogens with hydrogen peroxide for vaccine production | |
NZ618158A (en) | Compositions and methods for administration of vaccines against dengue virus | |
AR092896A1 (es) | Composiciones inmunogenicas | |
DOP2007000030A (es) | Nuevos productos farmacéuticos | |
NZ630831A (en) | Compositions and methods for administration of vaccines against dengue virus | |
AR088580A1 (es) | Metodos y composiciones para tratar el virus de la hepatitis c | |
WO2013104995A3 (en) | Compositions and methods for treating viral infections | |
CU20190013A7 (es) | Composiciones de vacunas multivalentes | |
ME01270B (me) | Cjepiva protiv zaraznog bronhitisa dobivena iz sojeva virusa sličnog ib-qx | |
CU20120057A7 (es) | Composición vacunal contra el virus del dengue, kit y plásmido | |
AR117191A1 (es) | Composiciones inmunogénicas | |
BR112013023354A2 (pt) | vacina para rinite equina | |
ECSP21087299A (es) | Composiciones y métodos para tratar el virus de la hepatitis c | |
AR097217A1 (es) | Composiciones inmunógenas de combinación | |
Hershey | Hepatitis A and B Protection with a Combination Vaccine Administered Using an Accelerated Schedule |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |